ERGOMED has a 13-year track record of the successful management of clinical development from Phase I through to Phase IV. The company operates throughout Europe, with a particular strength in Central and Eastern European countries and the MENA region (North Africa and Middle East). ERGOMED also operates in North America and across the globe and has been involved in  more than 100 studies treating over 10,000 patients at more than 800 sites.

ERGOMED specializes in the fields of Oncology/Hematology, Neurology, with added strengths in Allergy and Immunology while retaining a wide experience in a variety of other indications. For more details of indications where we have build a solid experience in the areas of Oncology/Hematology, Neurology and Allergy/Immunology please click on the relevant links.

The company has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors and other targeted agents, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies.
ERGOMED operates to the highest industry standards and uses state of the art management techniques. ERGOMED delivers excellent performance through the use of its unique Study Site Management model.